Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.46883/ONC.2021.3509.0562 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letter Regarding "Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study".
JTO Clin Res Rep
January 2025
Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan.
The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs-TKIs: A Retrospective Multicentric Study.
J Pers Med
September 2024
Unità Operativa di Radioterapia Oncologica, Casa di Cura Macchiarella, 90138 Palermo, Italy.
Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine-kinase inhibitor (TKI).
Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI-TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease.
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.
Liver Cancer
October 2024
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.
Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized.
Methods: Patients with advanced HCC who received immune checkpoint inhibitor (ICI)-based immunotherapy and achieved durable responses were retrospectively included. A durable response was defined as partial response (PR) or stable disease (SD) per RECIST 1.
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.
JTO Clin Res Rep
October 2024
Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia.
Introduction: The patterns of oligoprogression after first-line immune checkpoint inhibitors (ICIs) for metastatic NSCLC are yet to be well established. An increasing volume of data suggests that directed radiotherapy improves survival outcomes in patients with progression after ICIs.
Methods: A retrospective cohort study was performed on patients with metastatic NSCLC who had completed first-line programmed death-(ligand) 1 inhibitor therapy with or without chemotherapy at two high-volume cancer centers.
Single-Isocenter, Multiple-Target Abdominal Cone-Beam Computed Tomography (CBCT)-Guided Online Adaptive Stereotactic Body Radiotherapy (SBRT).
Cureus
September 2024
Radiation Oncology, Washington University School of Medicine, St. Louis, USA.
Stereotactic body radiotherapy (SBRT) is increasingly being prescribed for treating patients with multiple metastases, especially in the setting of oligometastatic disease. Treating multiple targets presents unique challenges in radiotherapy planning and delivery, including practical considerations relating to treatment time, resource allocation, and treatment planning complexity. Treating targets in a common isocenter reduces the time required for treatment and simplifies planning, but historically, it has often not been feasible due to inter- and intra-fractional variation in relative target positions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!